BCAT1 and neoplasm: Moreover, our investigation clearly showed the therapeutic potential of KH-3 in CRPC in vitro and in vivo, which is closely related to a decrease in BCAT1 expression and ERK5 activation, which is consistent with the idea that suppressing BCAT1 can inhibit tumour development [42–44].